Have you registered yet for Swiss HLG’s annual flagship conference 2024, being held at Grand Hotel Suisse Majestic, Montreux, on 26th – 28th May 2024?
We are delighted to share our exciting line-up of speakers and panelists who will be sharing their insights and expertise on conference topic “Back to deal making!” As access to capital became more challenging in recent times, biotechs turned to partnering as a key source of funding and the pace of dealmaking picked up. During the conference we will explore interesting new trends such as a focus on new therapy areas and AI.
In addition, there will be plenty of opportunities for networking and building new relationships with colleagues from around the world.
Swiss HLG and Benelux PLGB Live Webinar - 10 April 2023
Dealmaking in the Current Environment
Join us for this timely webinar on Wed, Apr 10, 2:30 PM - 4:00 PM (CET), where Nadine Maalouf, Managing Director at Van Lanschot Kempen will discuss M&A landscape and Fundraising in the EU, and Julia Schieber, Partner at Baker McKenzie will talk about M&A and Licenses. These two sessions will be followed by a live Q&A moderated by Luis Vieira, a Swiss HLG Board member.
Swiss Healthcare Licensing group is happy to announce the Swiss Healthcare Start- up Partnering Initiative. An educational program for early-stage healthcare companies to help them become partnering ready
This complimentary program is offered in collaboration with Johnson & Johnson Innovation and BaseLaunch, and consists of four linked workshops where leading experts will cover essential topics in healthcare business development.
We look forward to hosting you at our Swiss HLG Start-up Initiative workshops.
Please note that we request a commitment to attend all 4 complimentary workshops and to fund your own travel.
Our first networking event by Swiss HLG held at the Novartis Pavillon on the 21st November was a great success! The topic “Microbiome – from traditional Chinese remedies to the third phase of therapeutic objectives” was the theme for the evening.
Welcome to our new co-opted board member Nathalie Jenni
We have some exciting news: Swiss HLG would like to extend a warm welcome to our new co-opted board member Nathalie Jenni. With her close to 20 years of combined valuable experience and expertise as both in-house counsel and external independent attorney, Nathalie will bring new insights, ideas and opportunities to Swiss HLG and our members. We eagerly look forward to her input and contribution to our association.
Initiating her career at a commercial law firm in Basel, Switzerland, with her primary area of practice being contractual law and the pharmaceutical industry, Nathalie then moved to the biopharma industry where she spent 15 years as an in-house counsel. For over 12 years, Nathalie complemented business development teams, as the responsible signatory for legal matters as well as being a co-shaping and co-deciding part of the negotiation team for strategic and business relevant deals. Becoming independent at the end of 2021, she founded her own company in 2022.
Nathalie is a Swiss attorney and currently acts as a legal consultant and attorney for start-ups and SMEs in the biopharma field. She’s specialized on matters related to preclinical development and business development, with core expertise in and passion for complex licensing, collaboration and co-development agreements as well as option deals for compounds, cell therapies and vaccines.
Nathalie comments ¨I am delighted to join the Swiss HLG and help to foster a vibrant community of dealmakers in Switzerland, committed to enabling fair, balanced and beneficial deals¨.
Swiss HLG Basel Networking Event
Please join us for our inaugural Swiss HLG Basel Networking gathering on November 21st, where we will explore the topic of "Microbiome - from traditional Chinese remedies to the third phase of therapeutic objectives."
In recent years, the Microbiome has garnered significant attention as an emerging therapeutic approach. Nevertheless, many initiatives encounter challenges at various stages of their development. Throughout the evening, our goal is to delve deeper into the current landscape of Microbiome research, the ongoing transactions, as well as the strategies and novel business models being formulated by companies. Additionally, there will be plenty of opportunities to connect with fellow attendees during a networking apero in the exquisite setting of the Novartis Pavilion.
